Loading...
Loading...
Duncan Williams has upgraded Salix Pharmaceuticals
SLXP from Hold to Buy and has established a $47 price target.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Posted In: UpgradesPrice TargetAnalyst RatingsDuncan-Williams IncHealth CarePharmaceuticalsSalix Pharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in